Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the poster demonstrating the safety analysis of venetoclax, BCL-2 inhibitor, which has been approved for relapsed/refractory chronic lymphocytic leukemia (CLL) 17p patients. The analysis of 300 patients showed no new safety signals, only a small risk of laboratory tumor lysis syndrome, neutropenia and gastrointestinal toxicities. Dr Davids further discusses how patients on venetoclax show tolerance to the drug for long periods of time. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Safety analysis of the BCL-2 inhibitor venetoclax
